Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2017 • ACR Convergence 2020
Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis
Philip Mease¹, Désirée van der Heijde², Bruce Kirkham³, Georg Schett⁴, Ana-Maria Orbai⁵, Christopher Ritchlin⁶, Joseph Merola⁷, Luminita Pricop⁸, Xuan Zhu⁹, DavidA James⁹ and Gregory Ligozio⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸Novartis Pharmaceuticals Corporation, East Hanover, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Assessment of radiographic joint damage extent and progression is important in clinical trials evaluating treatments for psoriatic arthritis (PsA). Joint damage in patients with…
Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Johan Dalén¹, Karin Luttropp¹, Tor Olofsson², Christopher Black³ and Amy Puenpatom⁴, ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ³Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
Abstract Number: 0316 • ACR Convergence 2020
High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis
Siba Raychaudhuri¹, Yasser Abdelhafez², Soumajyoti Sarkar³, Smriti Raychaudhuri⁴ and Abhijit Chaudhari², ¹Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ²University of California, Davis, Sacramento, CA, ³University of California, Davis, Davis, ⁴VA Sacramento Medical Center, Davis, CA
Background/Purpose: To validate high-sensitivity PET/CT as a diagnostic test we have explored the association of total-body and extremity PET/CT measures with the standardized psoriatic arthritis…
Abstract Number: 0332 • ACR Convergence 2020
Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Jeffrey R Curtis¹, Iain McInnes², Proton Rahman³, William Tillett⁴, Philip Mease⁵, Alexa Kollmeier⁶, Elizabeth Hsia⁷, Bei Zhou⁸, Prasheen Agarwal⁸, Steven Peterson⁹ and Chenglong Han⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁶Janssen Research & Development, LLC, La Jolla, CA, ⁷Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific MAb Guselkumab (GUS) in PsA patients, who experience impaired physical function, resulting in…
Abstract Number: 0352 • ACR Convergence 2020
Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results
Josef Smolen¹, Anthony Sebba², Eric Ruderman³, Amanda Gellett⁴, Christophe Sapin⁴, Aubrey Sprabery⁴, Soyi Liu-Leage⁴, Sreekumar Pillai⁴, Paulo Reis⁴ and Peter Nash⁵, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Arthritis Associates, Palm Harbor, Tampa, FL, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting IL-17A, was superior to adalimumab (ADA) at Week (Wk) 24 for simultaneous achievement of ACR50 and…
Abstract Number: 0379 • ACR Convergence 2020
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in DMARD-Naive Patients Treated with Apremilast
Philip Mease¹, Arthur Kavanaugh², Alexis Ogdie³, Alvin Wells⁴, Martin Bergman⁵, Dafna Gladman⁶, Sven Richter⁷, Michele Brunori⁸, Lichen Teng⁷, Benoit Guerette⁷ and Josef Smolen⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²UC San Diego Health System, San Diego, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Aurora Rheumatology and Immunotherapy Center, Franklin, ⁵Drexel University College of Medicine, Philadelphia, PA, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Amgen Inc., Thousand Oaks, ⁸Amgen Europe GmbH, Rotkreuz, Switzerland, ⁹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase III PALACE 4 (NCT01307423) assessed the efficacy of apremilast (APR) in DMARD-naive patients with PsA. The Routine Assessment of Patient Index Data 3…
Abstract Number: 0583 • ACR Convergence 2020
Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis
Santos Castañeda¹, Esther Francisca Vicente-Rabaneda², Mar Llamas-Velasco³, Javier Sánchez-Pérez³, José Pardo⁴, Rita Cabeza-Martínez⁵, Mercedes Miranda-Fontes⁶, Juan Márquez⁷, Jaime Calvo-Alén⁸, Susana Armesto⁹, Isabel Belinchón¹⁰, Alejandro Gómez¹¹, María Dolores Miranda¹², Silvia Martínez-Pardo¹³, Leticia Merino Melendez¹⁴, Miguel Ángel Casado¹⁵, María Yébenes¹⁵ and Araceli Casado¹⁵, ¹Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ²Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁴H.G.U. Santa Lucía, Cartagena, Murcia, Spain, ⁵H.U. Puerta de Hierro Majadahonda, Madrid, Madrid, Spain, ⁶H.U. Río Hortega, Valladolid, Valladolid, Castilla y Leon, Spain, ⁷H.G. Jerez de la Frontera, Cádiz, Andalucia, Spain, ⁸Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ⁹H.U. Marqués de Valdecilla, Santander, Cantabria, Spain, ¹⁰H.G.U. Alicante, Alicante, Comunidad Valenciana, Spain, ¹¹H.U. Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain, ¹²H.G. San Agustín de Linares, Jaen, Andalucia, Spain, ¹³H. Mutua de Terrassa, Barcelona, Catalonia, Spain, ¹⁴H. San Pedro, Logroño, Spain, ¹⁵Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Madrid, Spain
Background/Purpose: Psoriasis (Ps) and psoriatic arthritis (PsA) have a major impact on patients’ health-related quality of life. Cost of illness of patients with Ps, PsA and…
Abstract Number: 0905 • ACR Convergence 2020
Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis
Philip Mease¹, Arthur Kavanaugh², Alexis Ogdie³, Alvin Wells⁴, Martin Bergman⁵, Dafna Gladman⁶, Frank Behrens⁷, Sven Richter⁸, Michele Brunori⁹, Lichen Teng⁸, Benoit Guerette⁸ and Josef Smolen¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²UC San Diego Health System, San Diego, CA, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Aurora Rheumatology and Immunotherapy Center, Franklin, ⁵Drexel University College of Medicine, Philadelphia, PA, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸Amgen Inc., Thousand Oaks, ⁹Amgen Europe GmbH, Rotkreuz, Switzerland, ¹⁰Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Apremilast (APR) is associated with comparable ACR response rates in DMARD-naive vs DMARD-experienced patients (pts) with PsA (Wells AF, et al. Rheumatology. 2018;57:1253-63; Kavanaugh…
Abstract Number: 1328 • ACR Convergence 2020
Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and troponin I (TnI) are established cardiac biomarkers that predict cardiovascular events (CVEs) and mortality in apparently healthy individuals…
Abstract Number: 1355 • ACR Convergence 2020
Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials
Philip Mease¹, Arthur Kavanaugh², Dafna Gladman³, Oliver FitzGerald⁴, Enrique Soriano⁵, Peter Nash⁶, Dai Feng⁷, Apinya Lertratanakul⁷, Kevin Douglas⁸, Ralph Lippe⁹ and Laure Gossec¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁵Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, ⁶School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ¹⁰Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France
Background/Purpose: Treat-to-target strategies in PsA recommend aiming for remission or low disease activity (LDA). Several disease activity measures are available including very low/minimal disease activity…
Abstract Number: 1549 • ACR Convergence 2020
Joint Damage and Malalignment Determine Articular Tenderness More Than Inflammation in Rheumatoid Arthritis, Psoriatic Arthritis or Osteoarthritis in Established Disease
Mihaela Popescu¹, Victoria Schimpl², Gabriela Supp³, Martina Durechova³, Paul Studenic³, Michael Zauner³, Josef Smolen³, Daniel Aletaha⁴, Peter Mandl³ and Irina Gessl³, ¹Hôpital Maisonneuve-Rosemont, Montreal, Canada, ²Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria
Background/Purpose: To determine whether clinical tenderness can be considered a sign of inflammatory joint activity in patients with rheumatoid arthritis (RA), osteoarthritis (OA) or psoriatic…
Abstract Number: 2021 • ACR Convergence 2020
The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Lihi Eder¹, Sibel Aydin² and Gurjit Kaeley³, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada, ³University of Florida College of Medicine - Jacksonville, Jacksonville, FL
Background/Purpose: DUET is a study supported by the Group for Assessment for Psoriasis and Psoriatic Arthritis (GRAPPA) that aims to develop a novel sonographic scoring…
Abstract Number: 0166 • ACR Convergence 2020
Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
Alexis Ogdie¹, George Gondo², Joseph Merola³, Stacie Bell⁴ and Alice Gottlieb⁵, ¹University of Pennsylvania, Philadelphia, PA, ²National Psoriasis Foundation, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ⁴National Psoriasis Foundation, Portland, ⁵Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Despite many efficacious therapies for PsA, many patients do not achieve remission. Ongoing disease activity leads to many downstream effects including diminished functional ability,…
Abstract Number: 0317 • ACR Convergence 2020
Axial Involvement in Psoriatic Arthritis in a Comprehensive Rapid Diagnosis Program (Reuma-check PsA). Analysis of Its Characteristics
Rodrigo Garcia Salinas¹, Santiago Ruta², Jessica Torres Chichande¹, Einer Sanchez Prado¹, Facundo Salvatori¹ and Sebastian Magri¹, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano La Plata, Buenos Aires, Argentina
Background/Purpose: To date, there is no consensus that allows an appropriate definition of axial involvement in PsA, that ranges between 25 to 70%. To estimate…
Abstract Number: 0333 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis
Denis Choquette¹, Loïc Choquette Sauvageau², Louis Bessette³, Isabelle Ferdinand², Boulos Haraoui⁴, Frédéric Massicotte², Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard², Diane Sauvageau², Édith Villeneuve² and Louis Coupal², ¹Institut de Rhumatologie de Montréal, Montreal, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Laval University, Quebec, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: The treatment of psoriatic arthritis has evolved with the addition of agents targeting a different cytokine, Il-17 introduced in 2016. It has proven to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].